Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with R/R myeloma

Natalia Neparidze • 3 Jun 2024
ASCO 2024
Multiple Myeloma Antibodies Belantamab mafodotin Elotuzumab

Natalia Neparidze, MD, Yale School of Medicine, New Haven, CT, discusses the findings of a Phase Ib/II study (NCT05002816) investigating the safety and tolerability of combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory (R/R) multiple myeloma (MM). This combination had a manageable safety profile with no dose-limiting toxicities (DLTs) reported and demonstrated encouraging preliminary efficacy in a heavily pretreated cohort of patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Natalia Neparidze

1:00
Racial differences in treatment and survival among older patients with multiple myeloma
Natalia Neparidze • 3 Jun 2024

Related Videos

5:30
Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-Ts
Sundar Jagannath • 3 Jun 2024
2:21
Cilta-cel versus SoC in functionally high-risk myeloma with one prior therapy
Luciano Costa • 2 Jun 2024
1:08
The impact of extramedullary multiple myeloma on outcomes with ide-cel
Saurabh Zanwar • 3 Jun 2024
0:49
The movement of BCMA-directed therapies to earlier lines in myeloma treatment
Amrita Krishnan • 2 Jun 2024
The content of VJHemOnc is intended for healthcare professionals